The BioPharm Brief: Advancing Parkinson, Kidney, Obesity and Cancer Care

Welcome to The BioPharm Brief, your daily snapshot of the latest developments shaping biopharmaceutical research, clinical progress, and therapeutic strategy. Today’s update looks at a potential Parkinson disease therapy moving toward clinical development, a new rare-disease partnership, flexible dosing strategies for obesity, and promising frontline lymphoma data.

First, Alector has granted Genentech exclusive worldwide rights to develop and commercialize AL050, an investigational brain-penetrant glucocerebrosidase, or GCase, enzyme replacement therapy for Parkinson disease and other neurodegenerative diseases. The therapy combines an engineered GCase enzyme with Alector’s Brain Carrier platform, designed to cross the blood-brain barrier. The program remains preclinical, but the approach aims to address GCase deficiency associated with Parkinson disease, including disease linked to GBA1 mutations.

That focus on addressing disease biology also extends to rare kidney disorders. CSL and Alentis Therapeutics have entered an exclusive global collaboration to develop lixudebart, an investigational antibody targeting claudin-1. The lead indication is anti-neutrophil cytoplasmic antibody-associated vasculitis with rapidly progressive glomerulonephritis, or AAV-RPGN. Early phase 2 data showed improvements in kidney function, although the interim analysis included just 26 patients. The companies also plan to study lixudebart in focal segmental glomerulosclerosis and primary sclerosing cholangitis.

Meanwhile, obesity developers are increasingly looking beyond initial weight loss toward long-term treatment flexibility. Viking Therapeutics has begun Part 2 of a maintenance study evaluating daily and weekly oral VK2735 tablets, as well as less-frequent injections, after 21 weeks of weekly subcutaneous treatment. Earlier results showed participants retained much of their initial weight loss with less-frequent dosing, supporting further evaluation of maintenance strategies.

And in oncology, epcoritamab combined with R-CHOP significantly improved progression-free survival in the phase 3 EPCORE DLBCL-2 trial in newly diagnosed diffuse large B-cell lymphoma. The topline results could support regulatory discussions for using the subcutaneous bispecific antibody in the frontline setting, although overall survival and detailed safety data have not yet been reported.

These developments serve to highlight efforts by industry to move beyond established treatment approaches, from targeting disease mechanisms and improving drug delivery to making therapies more flexible and advancing bispecific antibodies into earlier lines of care.

Thanks for listening to The BioPharm Brief. For further analysis and expert insights, please visit www.BioPharmInternational.com.

Key takeaways

• AL050 uses a brain-penetrant approach to target GCase deficiency in Parkinson disease, but remains preclinical.
• Lixudebart and VK2735 illustrate efforts to expand treatment options and dosing flexibility in rare and chronic diseases.
• Epcoritamab plus R-CHOP improved progression-free survival in newly diagnosed DLBCL, supporting further regulatory evaluation.